

Urology-Specific QCDR Ready for 2018 Reporting

Earlier this year, Intrinsic Specialty Solutions began offering a QCDR (Quality Clinical Data Registry) to UroChart practices utilizing Quality Reporting Engagement Group services. The QCDR is a Centers for Medicare & Medicaid Services-approved entity that collects data from individual MIPS-eligible clinicians, groups and/or virtual groups for data submission.

Those MIPS-eligible providers can submit a broader set of measures, including up to 30 measures approved by CMS.

This QCDR was created to provide urology-specific metrics needed to ensure future success in reporting Quality measures for UroChart customers. Several of these measures are proprietary to Intrinsic Specialty Solutions. In addition to the current Quality measures in UroChart, the QCDR will provide seven additional urology-specific measures that can be measured and reported directly out of UroChart in 2018. Because the measures are more relevant to urology, professionals are more motivated to achieve a better performance rate.

The Urology-specific measures include:

- Bone-Density Evaluation for Patients with Prostate Cancer & Receiving Androgen Deprivation Therapy (ADT)
- Hypogonadism: Serum T, CBC, IPSS within 6 months of Rx
- Prostate Cancer: Newly Diagnosed with document T, PSA, Gleason
- Prostate Cancer: Treatment Options Counseling
- Prostate Cancer: Follow-up Testing for patients on active surveillance for at least 30 months
- BPH: Anticholinergics
- Counseling SU1

Data extraction for reporting will be automatic, and trending reports will be provided by the Quality Reporting Engagement Group account manager. For the first year of the QCDR, all QCDR-specific measures will not have benchmarks for scoring. Instead, CMS will create benchmarks based on data submitted after the performance year is complete (Jan-Mar 2019).

For more information on participation in the QCDR or specifics for reporting, contact sales@intrinsic.com.